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ABSTRACT
Background: The percutaneous closure of a patent ductus 
arteriosus (PDA) has been considered the treatment of choice 
by most authors, and several devices with different structural 
characteristics have been used. The initial experience with the 
novel CeraTM PDA Occluder is reported. Methods: From March 
of 2010 through December of 2011, patients weighing over 
5 kg with a PDA diagnosed by transthoracic echocardiogram 
(TTE) with colour Doppler flow mapping and no associated 
defects underwent the procedure. Follow-up was performed 
by TTE one, three, and six months after the procedure, and 
yearly thereafter. Results: Overall, 18 patients were referred 
for percutaneous occlusion; 61.2% were female. The mean 
age and weight were 13.7  ±  9.3 years and 42.9  ±  20.1  kg, 
respectively. Regarding morphology, 11 were type A, six were 
type E, and one had a residual postoperative defect. The 
mean diameter was 4.2 mm. Implantation was possible in all 
patients. Ten 6-4 mm, one 8-6 mm, three 10-8 mm, and four 
12-10  mm devices were used. All defects were completely 
closed by the first follow-up TTE. Deaths or complications were 
not observed in this series. Conclusions: The CeraTM prosthesis 
may be used for the occlusion of small or large defects, and 
delivers to excellent results in children and adults. The pro-
cedure is easy, safe, has a high efficacy and low morbidity, 
and may be an excellent option for the percutaneous closure 
of a PDA. Due to its flexibility, oversized devices greater than 
2 mm should be used. 
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RESUMO
Fechamento de Canais Arteriais com o  
Dispositivo CeraTM PDA Occluder: Mais uma  
Boa Opção na Caixa de Ferramentas
Introdução: O fechamento percutâneo de persistência dos ca -
nais arteriais (PCA) tem sido considerado tratamento de escolha 
pela maioria dos autores, e diversos dispositivos com diferentes 
características estruturais têm sido utilizados. Apresentamos a 
experiência inicial do grupo com a nova pró tese CeraTM PDA 
Occluder. Métodos: Entre março de 2010 e dezembro de 2011 
foram submetidos ao procedimento pacientes com mais de 5 kg 
de peso, com PCA diagnosticada por meio de ecocardio grama 
transtorácico com mapeamento de fluxo em cores (ETT), sem 
defeitos associados. O seguimento foi feito com ETT no primeiro, 
no terceiro e no sexto meses subsequentes, e, a seguir, anualmente. 
Resultados: No total, 18 pa cientes foram encaminhados para 
oclusão percutânea, dos quais 61,2% eram do sexo feminino. 
As médias das idades e dos pesos foram, respectivamente, de 
13,7 ± 9,3 anos e 42,9 ± 20,1 kg. Quanto à morfologia, 11 
canais foram do tipo A, 6 foram do tipo E, e 1 pertuito residual 
após cirurgia. A média dos diâmetros foi de 4,2 mm. O implante 
foi possível em todos os casos. Foram utilizadas 10 próteses 
6-4 mm, 1 prótese 8-6 mm, 3 próteses 10-8 mm e 4 próteses 
12-10 mm. Todos os canais estavam completamente fechados 
por ocasião do primeiro ETT de controle. Não houve óbitos ou 
com plicações nesta casuís tica. Conclusões: A prótese CeraTM 
pode ser utilizada para o fechamento de canais de pequeno 
ou grande calibres com excelente resultado, em crianças e 
adultos. O procedimento é fácil, seguro, com alta eficácia e 
baixa morbidade, e pode ser excelente opção para o fechamento 
percutâneo de PCA. Suas características de flexibilidade sugerem 
que sejam utilizadas próteses superdimensionadas acima dos 
2 mm habitualmente recomendados.
DESCRITORES: Permeabilidade do canal arterial. Cateterismo 
car díaco. Próteses e implantes. Cardiopatias congênitas.
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T he percutaneous closure of a patent ductus arte-riosus (PDA) represents an established alternative to surgical ligation and has been defined as the 
treatment of choice by most authors. To this end, several 
devices have been used.1–15
At the end of the 1990s, the first metal mesh 
prosthesis, the Amplatzer® Duct Occluder I (ADO I), 
capable of occluding larger diameter channels was 
developed as an alternative to embolisation coils.16 
Universally used, it has occlusion rates of nearly 
100%, with very low short- and long-term complica-
tion rates.17–20 Despite the success, new devices with 
different structural characteristics have been produced.
The objective of the present study was to present an 
initial experience with a new prosthesis, the CeraTM PDA 
Occluder (Lifetech Scientific Co. Ltd., Shenzhen, China), 
and to examine its role as another option for the occlu-
sion of medium and large calibre PDA. 
METHODS
Study design
This was a prospective, single-arm study performed 
at two centres. All patients underwent closure of PDA 
with the CeraTM prosthesis between March 2010 and 
December 2011. Characteristics of the device and the 
immediate results are described.
Selection criteria
All consecutive patients weighing more than 5 kg 
with PDA, and without any other associa ted defects that 
required surgical correction, were included in this study. 
Cases were chosen by transthoracic echocardiograms 
(TTEs) with colour flow mapping. The dimensions and 
morphology of the defects did not constitute exclusion 
criteria.
The prosthesis
The CeraTM occluder is a self-expansible prosthesis 
with a nitinol fragmented cone and ceramic coating. 
The proximal (pulmonary) extremity has a female thread, 
measuring 2 mm less than the distal (aortic) extremity 
of the cone, and connects to the delivery system. There 
is a retention disc in the aortic extremity that measures 
4  mm more than the distal extremity (Figure 1).
The device is available in 2-mm increments from 
6  mm to 24  mm in diameter (distal extremity). The 
central portion measures 7 mm in 6- to 14-mm prostheses, 
8 mm in 16- and 18-mm prostheses, 9 mm in 20- and 
22-mm prostheses, and 10  mm in 24-mm prostheses.
The delivery system is composed of a 5 F to 12 F 
long and flexible sheath, a small loader of compatible 
size, a haemostatic valve, and a distal extremity with 
a metallic cable with threads.
Implant technique
The implant and follow-up protocols have been 
previously described and are the same protocols used 
for the ADO I prosthesis study.20
Statistical analysis
Continuous variables were expressed as mean and 
standard deviation, while categorical variables were 
expressed as numbers and percentages. The objective 
of this article was to present the initial experience with 
the new CeraTM prosthesis for the treatment of PDA in a 
single-arm registry; therefore, comparisons were not made.
RESULTS
Eighteen patients were referred for percutaneous 
closure with the CeraTM prosthesis; 61.2% were female. 
Their ages ranged from 1 to 33 years (13.7  ±  9.3 
years), and their weights ranged from 10  kg to 72  kg 
(42.9  ±  20.1  kg).
Two patients had recent onset of exertional dyspnoea 
(cases 17 and 18). Regarding the morphology, 11 chan-
nels were type A, six were type E,21 and the other was 
a residual channel after surgical ligation.
The smaller channel diameters, measured at the 
pulmonary extremity, ranged from 1  mm to 8.6  mm 
(4.2  ±  2.4  mm) (Table).
The systolic pulmonary pressure was higher than 
30  mmHg in 50% (9/18) of patients and ranged from 
18  mmHg to 45  mmHg (31  ±  7.9  mmHg).
Implantation of the device was possible in all cases. 
Ten 6-4  mm, one 8-6  mm, three 10-8  mm, and four 
12-10  mm prostheses were used.
Figure 1 – Two details of the CeraTM PDA Occluder. The retention disc 
can be observed in the aortic extremity and the thread in the opposed 
extremity connected to the releaser cable. The presence of expanded 
polytetrafluorethylene inside the prosthesis to increase its occlusive 
capacity can be noticed.
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At the end of the procedure, two patients had 
minimal leakage of contrast inside the device; however, 
all defects were completely closed on the first control 
TTE, which was performed within the first week after 
the procedure (Figure 2). A gradient in the descending 
aorta or in the left branch of the pulmonary artery was 
not observed. In this initial series, complications were 
not observed.
DISCUSSION
The percutaneous closure of a PDA has been suc-
cessfully performed through the use of several devices. 
The introduction of the ADO I prosthesis brought safety 
and ease of use, with excellent occlusion rates (99% 
to 100%) and a low incidence of complications (0% to 
7%). This constituted an excellent alternative to per-
cutaneous coil closure, despite the higher cost. The 
reported complications, in general, are minor and are 
usually observed in more severe patients and in patients 
with less body weight.22,23 There are no reports of late 
complications with this device.24
The Nit-Occlud® (PFM, Cologne, Germany) device 
was introduced as an intermediate device between the 
ADO I and coils. It utilises a controlled-release pre-
molded coil that is shaped as an inverted double cone. 
It is capable of occluding intermediate size channels 
(< 6 mm) and costs less. With an occlusion rate of 91% 
to 100% and few minor complications (0% to 9%), it 
has been used in some centres, including in Brazil.25–28
The Amplatzer® Duct Occluder II (ADO II) was 
developed to occlude channels in smaller children by 
reducing the introducer profile. It maintained the high 
occlusion rate of existing devices. With two articulated 
disks at the extremities and a central portion, it closes 
channels of less than 12  mm in length and less than 
5.5 mm in diameter. Occlusion rates were maintained 
at nearly 100%, without reports of significant com-
plications.29–33 The report of a case in which residual 
flow appeared 24 hours after the successful closure of 
a 3 mm channel due to kinking of the left disc in the 
ductal ampoule should be highlighted.34
TABLE 
Characterisation of the Study Population
Case 
No.
ID Gender
Age 
(years)
Weight 
(kg)
Morphologic 
type
Diameter  
(mm)
Size of the
device*
Results
1 JOC M 27 70 A 6 CPO 12 Closed
2 ASC F 17 56 A 5 CPO 10 Closed
3 JSO F 5 14 A 5 CPO 10 Closed
4 CGNA F 12 44 E 1 CPO 6 Closed
5 ACLO F 18 49 E 8.6 CPO12 Closed
6 GBB M 20 72 E 1 CPO 6 Closed
7 LHL F 20 55 A 1 CPO 6 Closed
8 JPAU M 1 10 A 1 CPO 6 Closed
9 DHDT M 14 73 E 1 CPO 6 Closed
10 KRC F 10 50 A 1 CPO 6 Closed
11 ACPO F 13 40 A 6 CPO 10 Closed
12 MRFS M 12 50 E 1 CPO 6 Closed
13 GRB F 8 30 PO 1 CPO 6 Closed
14 CVPS F 3 26 E 1 CPO 8 Closed
15 ALCA F 3 15 A 2.5 CPO 6 Closed
16 TAS M 2 12 A 2 CPO 6 Closed
17 SLRM M 33 57 B 8 CPO 12 Closed
18 LSG F 30 50 A 7 CPO 12 Closed
* The number corresponds to the diameter of the distal end (aortic end) of the central portion of the device.  
CPO = CeraTM PDA Occluder; F = female; ID = identification; M = male; PO = post-operative.
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The design of the CeraTM prosthesis is very similar 
to that of the ADO I, but it has a more flexible nitinol 
mesh and a ceramic coating. This characteristic gives 
the CeraTM prosthesis the theoretical advantage of less 
nickel release on the days after the implant, although 
this has not been a problem reported with the ADO I.
Its great flexibility allows for the supersizing  of the 
prosthesis according to the channel diameter without 
damaging neighbouring structures. Hence, the prosthesis 
is more stable (greater constriction in its central portion), 
and, as a consequence, it has a lower embolisation risk.
The long introducer allows passage through accen-
tuated curves without kinks or breaks. Another advantage 
is the presence of a radiopaque mark in the distal end, 
which allows the surgeon to safely know the position of 
the long sheath during all the steps of the procedure.
CONCLUSIONS
In this initial experience, the CeraTM prosthesis 
could be used in small or large calibre channels. This 
device was easy to use, was extremely safe, had a low 
risk of morbidity, and was highly effective. The implant 
procedure is very similar to that of other existing nitinol 
mesh prostheses.
The author believe that its greater flexibility allows 
its diameter to be supersized more than 2  mm above 
the smaller channel diameter.
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